Metastatic uveal melanoma: Biology and emerging treatments

Cancer Journal

Volumn 18, Issue 2, 2012, Pages 148-152

  Woodman, Scott E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BAP1; GNA11; GNAQ; Uveal melanoma

Indexed keywords

CABOZANTINIB; CARBOPLATIN; CRIZOTINIB; EMD 1204831; EVEROLIMUS; FORETINIB; GANETESPIB; OBLIMERSEN; ONARTUZUMAB; PACLITAXEL; PASIREOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; SELUMETINIB; SUNITINIB; TEMOZOLOMIDE; TICILIMUMAB; TIVANTINIB; TRAMETINIB; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 3; CHROMOSOME LOSS; CYTOGENETICS; GENE; GENE MUTATION; GNA11 GENE; GNAQ GENE; HUMAN; MELANOCYTE; METASTASIS; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; UVEA MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; HUMANS; MELANOMA; MUTATION; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; UVEAL NEOPLASMS;

EID: 84859475466     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31824bd256     Document Type: Review

References (46)

1. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46:151-166. (Pubitemid 44124237)
2. McLean IW, Saraiva VS, Burnier MN Jr. Pathological and prognostic features of uveal melanomas. Can J Ophthalmol. 2004;39:343-350. (Pubitemid 38886327)
3. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222-1225. (Pubitemid 26131850)
4. Onken MD, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205-7209. (Pubitemid 39372052)
5. Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol. 2008;4:629-636.
6. Harbour JW. Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol. 2009;148:823-829.e1.
7. Vaarwater J, van den Bosch T, Mensink HW, et al. Multiplex ligationY dependent probe amplification equals fluorescence in-situ hybridization for the identification of patients at risk for metastatic disease in uveal melanoma. Melanoma Res. 2012;22:30-37.
8. Munzenrider JE. Uveal melanomas. Conservation treatment. Hematol Oncol Clin North Am. 2001;15:389-402.
9. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670-676.
10. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383-389; discussion 390.
11. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219-2223. (Pubitemid 23280150)
12. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44: 4651-4659. (Pubitemid 37315273)
13. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer. 2004;100: 122-129. (Pubitemid 37553547)
14. Aoki H, Yamada Y, Hara A, et al. Two distinct types of mouse mela-nocyte: differential signaling requirement for the maintenance of non-cutaneous and dermal versus epidermal melanocytes. Development. 2009;136:2511-2521.
15. Van Raamsdonk CD, Fitch KR, Fuchs H, et al. Effects of G-protein mutations on skin color. Nat Genet. 2004;36:961-968. (Pubitemid 39167492)
16. Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46:2253-2257. (Pubitemid 43119466)
17. Hausler T, Stang A, Anastassiou G, et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int J Cancer. 2005;116:909-913. (Pubitemid 41209197)
18. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19:22-28. (Pubitemid 27193716)
19. Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res. 1999;59:3032-3037. (Pubitemid 29315995)
20. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191-2199.
21. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49: 5230-5234.
22. Bauer J, Kilic E, Vaarwater J, et al. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer. 2009;101:813-815.
23. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410-1413.
24. Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hy-drolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16:1097-1112. (Pubitemid 28127509)
25. Machida YJ, Machida Y, Vashisht AA, et al. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem. 2009;284:34179-34188.
26. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature. 2010;465:243-247.
27. Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18:408-416.
28. Weber A, Hengge UR, Urbanik D, et al. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest. 2003;83:1771-1776. (Pubitemid 38018540)
29. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer. 2005;92:2032-2038. (Pubitemid 40897426)
30. Woodman SE, Hayes B, Stemke-Hale K, et al. Targeting genetic aberrations in uveal melanoma. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; 2010; Fort Lauderdale, FL.
31. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009; 457:599-602.
32. Saraiva VS, Caissie AL, SegalL, et al. Immunohistochemical expression of phosphor-Akt in uveal melanoma. Melanoma Res. 2005;15:245-250. (Pubitemid 41127459)
33. Populo H, Soares P, Rocha AS, et al. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res. 2010;20: 107-117.
34. Ballou LM, Chattopadhyay M, Li Y, et al. Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras. Biochem J. 2006;394:557-562.
35. Howes AL, Miyamoto S, Adams JW, et al. Galphaq expression activates EGFR and induces Akt mediated cardiomyocyte survival: dissociation from Galphaq mediated hypertrophy. J Mol Cell Cardiol. 2006;40: 597-604.
36. Abdel-Rahman MH, Yang Y, Zhou XP, et al. High frequency of sub-microscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol. 2006;24:288-295. (Pubitemid 46622057)
37. Abdel-Rahman MH, Boru G, Massengill J, et al. METoncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci. 2010;51:3333-3339.
38. Economou MA, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Acta Ophthalmol. 2008;86 Thesis 4:20-25.
39. Mallikarjuna K, Pushparaj V, Biswas J, et al. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res. 2007;32: 281-290. (Pubitemid 46439685)
40. Topcu-Yilmaz P, Kiratli H, Saglam A, et al. Correlation of clinicopath-ological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 20:126-132.
41. All-Ericsson C, Girnita L, Seregard S, et al. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 2002;43:1-8. (Pubitemid 34032432)
42. Economou MA, Andersson S, Vasilcanu D, et al. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:2337-2342.
43. Woodman SE, Yu X, Chattopadhyay C, et al. GNAQ/11 mutant dependent uveal melanoma sensitivity to MEK and PI3K inhibitors. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; 2011; Fort Lauderdale, FL.
44. Patel M, Smyth E, Chapman PB, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011; 17:2087-2100.
45. Bedikian AY, Papadopoulos N, Plager C, et al. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res. 2003; 13:303-306. (Pubitemid 36683775)
46. V600E mutation. N Engl J Med. 2010;364:2507-2516.